Novel Therapies on the Horizon for Waldenström Macroglobulinemia
New treatments are in clinical development for Waldenström macroglobulinemia, a disease for which there is unmet clinical need.
Hematologic Cancers
Biosimilar Truxima Now Available for Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
Truxima (rituximab-abbs; Teva and Celltrion), a biosimilar to Rituxan (rituximab; Genentech) will be available in the US the week of November 11, 2019 for the treatment of adults with non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL).
Hematologic Scoring System Predicts Survival in Multiple Myeloma
A hematologic score based on specific blood parameters was evaluated for its potential to predict survival in patients with newly diagnosed multiple myeloma.
Exercise Intolerance, Neurocognitive Dysfunction in Survivors of Childhood Acute Lymphoblastic Leukemia
Exercise tolerance was found to be associated with verbal fluency, dominant motor speed, and math academics, among other neurocognitive metrics.
Reduced Rates of Central Nervous System Relapse in Patients With High-Risk Pediatric ALL
Central nervous system relapse rates in pediatric acute lymphoblastic leukemia can be reduced with additional early doses of intrathecal chemotherapy.
Single-Cell RNA Sequencing Characterizes T-Cell Impairment in CAR-T Cells Derived From Patients With CLL
This study investigated whether T-cell gene-expression profiles and other molecular characteristics of T-cell populations were associated with CAR-T performance.
Treosulfan May Offer a New Standard for Prehematopoietic Stem Cell Transplantation Conditioning
Patients receiving treosulfan and fludarabine experienced improved event-free and overall survival compared with patients receiving busulfan and fludarabine.
Expert Q&A: Addressing the Survivorship Gap in Pediatric Hodgkin Lymphoma
Refining primary treatment and emphasizing secondary treatment can help mitigate the survivorship gap faced by many pediatric survivors of HL.
Off-the-Shelf CAR T Cells From Umbilical Cord Blood Show Unique Features
Anti-CD19 chimeric antigen receptor T cells made from umbilical cord blood cells had a distinct phenotype and may offer off-the-shelf potential.
19-28z CAR-T Therapy in Children and Young Adults With Relapsed/Refractory ALL: Promising Early Results
The response rate to 19-28z CAR-T therapy was 100% for those with pretreatment MRD who received preconditioning chemotherapy with high-dose cyclophosphamide.
Next post in Hematologic Cancers
